A focused gene therapy company
Lowering LMNB1 to change the course of ADLD.
OligoVale is developing a one-time gene therapy for autosomal dominant leukodystrophy, a fatal, ultra-rare disease with no approved treatment.
We exist to bring the first treatment to people living with ADLD.
Why ADLD
A devastating disease with a clear genetic driver.
Autosomal dominant leukodystrophy is caused by overexpression of LMNB1. Too much LMNB1 disrupts myelin in the central nervous system, driving a progressive disease that affects people in adulthood.
Ultra-rare
Adult-onset
No approved therapy
Our approach
Designed to address the cause of ADLD.
Our approach delivers an RNA-silencing payload with an oligodendrocyte-targeted AAV, aiming to lower LMNB1 toward normal levels in the cells where the disease begins.
Excess LMNB1
LMNB1 overexpression disrupts myelin and drives disease progression.
Targeted delivery
An AAV carries an RNA-silencing payload to oligodendrocytes.
Toward normal
The payload is designed to lower LMNB1 toward normal levels.
Our lead program
OV-1
One program. One clear purpose.
OV-1 is focused on lowering LMNB1 in oligodendrocytes, with the goal of halting the progression of ADLD. Our work is building the evidence needed to advance this focused therapeutic approach.
Indication
Autosomal dominant leukodystrophyTarget
LMNB1Approach
AAV-delivered RNA silencingOur origin
Built from a deep commitment to the ADLD community.
OligoVale was spun out of the ADLD Center, bringing together focused disease knowledge, patient research, and a therapeutic program built around the biology of ADLD.
Our storyA focused path forward
Science in service of people living with ADLD.
We welcome conversations with researchers, partners, and members of the ADLD community who share our commitment to changing the course of this disease.